Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | TLR2 | O60603 | 4/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157861 | 0.91 | HDAC1 (0.61) | HDAC1HDAC2TNF | |
| SCHEMBL6159625 | 0.91 | HDAC1 (0.61) | HDAC1HDAC2TNF | |
| SCHEMBL6157856 | 0.91 | HDAC1 (0.61) | HDAC1HDAC2TNF | |
| SCHEMBL9932972 | 0.90 | SIRT2 (0.61) | HDAC1HDAC2TLR2SIRT2SIRT1 | |
| SCHEMBL9932973 | 0.90 | SIRT2 (0.61) | HDAC1HDAC2TLR2SIRT2SIRT1 | |
| SCHEMBL16327875 | 0.90 | HDAC1 (0.60) | HDAC1HDAC2TLR2 | |
| SCHEMBL10088326 | 0.90 | HDAC1 (0.60) | HDAC1HDAC2TLR2 | |
| SCHEMBL16181596 | 0.90 | HDAC1 (0.60) | HDAC1HDAC2TLR2 | |
| SCHEMBL30424446 | 0.90 | HDAC1 (0.60) | HDAC1HDAC2TLR2 | |
| SCHEMBL13561436 | 0.89 | HDAC1 (0.60) | HDAC1HDAC2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | HDAC1 4823/4885HDAC2 4873/4885TLR2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.